Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of non-viral EPHB4-CAR-T cells in advanced solid tumors (ancillary kinetics/mechanism study)
jRCT1030240137Phase 1Recruiting
- Sponsor
- National Cancer Center Hospital
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EPHB4-CAR-T cells in Ewing sarcoma and Nonhematologic neoplasms, sponsored by National Cancer Center Hospital. Primary endpoints: Incidence of secondary cancer and Incidence of delayed toxicity. Started Jun 2024; status: recruiting.
02
Drugs
EPHB4-CAR-T cells
03
Conditions
Ewing sarcomaNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT1030240137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030240137.